Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Body surface area and medication dosing in patients with heart failure with reduced ejection fraction

Trends in Cardiovascular Medicine(2020)10.1016/j.tcm.2019.12.011Source: DataRank Database

Body surface area and medication dosing in patients with heart failure with reduced ejection fraction is a research paper published in Trends in Cardiovascular Medicine (2020). On theSindex it has a DataRank of 0.330. It has been cited 8 times.

N/A

0.330DataRank · unranked

Scored on demand from live citation data

8 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 0.55)OA: closedTopics (36)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.330

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (4)

Stephen J. Greene ORCID,Tracy A. DeWald,Robert J. Mentz ORCID,Jeremy Brooksbank

Live enrichment

PubMed:32008834 OpenAlex:https://openalex.org/W2998775369

National Institutes of Health

Grant: R01AG045551-01A1

National Institutes of Health

Grant: U01HL125511-01A1

Bristol-Myers Squibb

Heart Failure Society of America

Gilead Sciences

Merck

Bayer Fund

GlaxoSmithKline

Luitpold Pharmaceuticals

AstraZeneca

Boston Scientific Corporation

Janssen Pharmaceuticals

Medtronic

Amgen

Abbott Laboratories

Novartis

FWCI

0.55

Citation Percentile

0.7%

Citation Trend

2020

2022

2023

2024

2025

closedLicense: https://www.elsevier.com/legal/tdmrep-license

publisherhttps://api.elsevier.com/content/article/PII:S1050173820300050?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1050173820300050?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.tcm.2019.12.011

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32008834

Fields of Study

Heart Failure Treatment and ManagementBlood Pressure and Hypertension StudiesMedication Adherence and ComplianceBody Surface AreaCardiovascular AgentsDrug Dosage CalculationsHeart FailureHumansMaximum Tolerated DoseRecovery of FunctionStroke VolumeTreatment OutcomeVentricular Function, Left

MeSH Terms

Body Surface AreaCardiovascular AgentsHeart FailureHumansStroke VolumeVentricular Function, LeftTreatment OutcomeRecovery of FunctionMaximum Tolerated DoseDrug Dosage Calculations

Keywords

DosingBody surface areaMedicineTolerabilityHeart failureEjection fractionIntensive care medicineBlood pressureInternal medicineCardiologyAdverse effectTarget DoseMedication Dose

Sustainable Development Goals

SDG 0: Good health and well-being

Body surface area and medication dosing in patients with heart failure with reduced ejection fraction

FAIR Checklist

DataRank Breakdown

Authors (4)

Funding (16 grants)

Impact

Open Access

Topics